ARIES 144 week results: durable virologic suppression in HIV-infected patients simplified to unboosted atazanavir/abacavir/lamivudine. (Q51349356)

4 April 2018

title

ARIES 144 week results: durable virologic suppression in HIV-infected patients simplified to unboosted atazanavir/abacavir/lamivudine. (English)

1 reference

4 April 2018

0 references

1 reference

Kathleen E Squires

1

1 reference

4 April 2018

Benjamin Young

2

1 reference

4 April 2018

Edwin DeJesus

3

1 reference

4 April 2018

Nicholaos Bellos

4

1 reference

4 April 2018

Daniel Murphy

5

1 reference

4 April 2018

Douglas Ward

6

1 reference

4 April 2018

Henry H Zhao

7

1 reference

4 April 2018

Lisa L Ross

8

1 reference

4 April 2018

Mark S Shaefer

9

1 reference

4 April 2018

ARIES Study Team

10

1 reference

4 April 2018

publication date

1 September 2012

1 reference

4 April 2018

published in

HIV Clinical Trials

1 reference

4 April 2018

volume

13

1 reference

4 April 2018

issue

5

1 reference

4 April 2018

page(s)

233-244

1 reference

4 April 2018

Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel

cites work

1 reference

https://api.crossref.org/works/10.1310%2FHCT1305-233

Toxicity of antiretroviral therapy and implications for drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1305-233

The role of pharmacological enhancement in protease inhibitor-based highly active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1305-233

Postprandial lipid effects of low-dose ritonavir vs. raltegravir in HIV-uninfected adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1305-233

Impact of different low-dose ritonavir regimens on lipids, CD36, and adipophilin expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1305-233

Investigation of low-dose ritonavir on human peripheral blood mononuclear cells using gene expression whole genome microarrays

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1305-233

Safety and efficacy of a 36-week induction regimen of abacavir/lamivudine and ritonavir-boosted atazanavir in HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1305-233

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1305-233

A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1305-233

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1305-233

Unboosted atazanavir-based therapy maintains control of HIV type-1 replication as effectively as a ritonavir-boosted regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1305-233

A randomized, pilot trial to evaluate glomerular filtration rate by creatinine or cystatin C in naive HIV-infected patients after tenofovir/emtricitabine in combination with atazanavir/ritonavir or efavirenz

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1305-233

Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1305-233

Abacavir/lamivudine versus tenofovir DF/emtricitabine as part of combination regimens for initial treatment of HIV: final results

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1305-233

Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1305-233

Once-daily abacavir/lamivudine and ritonavir-boosted atazanavir for the treatment of HIV-1 infection in antiretroviral-naïve patients: a 48-week pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1305-233

Efficacy and safety of a switch to unboosted atazanavir in combination with nucleoside analogues in HIV-1-infected patients with virological suppression under antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1305-233

21 January 2018

Identifiers

DOI

10.1310/HCT1305-233

1 reference

4 April 2018

PubMed ID

23134624

1 reference

4 April 2018